Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC).
Adipokines
Immunotherapy
Leptin
Metabolomics
Obesity
SCLC
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
25
06
2023
accepted:
20
08
2023
medline:
23
10
2023
pubmed:
5
9
2023
entrez:
5
9
2023
Statut:
ppublish
Résumé
Only few ES-SCLC patients experience long-term survival benefit by maintenance IT. Adipokines-induced metabolic meta-inflammation has been related to enhanced responsiveness to IT in obese patients; however, their prognostic role in SCLC is currently controversial. Pre-treatment CT scan was used for determining distribution of abdominal adiposity, and blood samples were collected at fasting for measuring glycemia, insulin, ghrelin, leptin and adipokines (TNF-α, IFN-γ, IL-6 and MCP-1). Patients with known history of DM type II or metabolic syndrome with HOMA index > 2.5 were considered insulin resistant (IR). In ES-SCLC pts receiving maintenance IT, increased leptin concentration and higher leptin/visceral adipose tissue (VAT) ratio were significantly associated with prolonged PFS. By applying a hierarchical clustering algorithm, we identified a cluster of patients characterized by higher leptin values and lower pro-inflammatory cytokines (TNF-α, IFN-γ and IL-6) who experienced longer PFS (13.2 vs 8.05 months; HR: 0.42 [0.18-0.93] p = 0.02) and OS (18.04 vs 12.09 mo; HR: 0.53 [0.25-1.29] p = 0.07). Adipokines can play a crucial role to determining effectiveness of anti-cancer immunotherapy. The role of metabolic immune dysfunctions needs further pre-clinical validation and is currently investigated in the larger prospective cohort.
Sections du résumé
BACKGROUND
BACKGROUND
Only few ES-SCLC patients experience long-term survival benefit by maintenance IT. Adipokines-induced metabolic meta-inflammation has been related to enhanced responsiveness to IT in obese patients; however, their prognostic role in SCLC is currently controversial.
METHODS
METHODS
Pre-treatment CT scan was used for determining distribution of abdominal adiposity, and blood samples were collected at fasting for measuring glycemia, insulin, ghrelin, leptin and adipokines (TNF-α, IFN-γ, IL-6 and MCP-1). Patients with known history of DM type II or metabolic syndrome with HOMA index > 2.5 were considered insulin resistant (IR).
RESULTS
RESULTS
In ES-SCLC pts receiving maintenance IT, increased leptin concentration and higher leptin/visceral adipose tissue (VAT) ratio were significantly associated with prolonged PFS. By applying a hierarchical clustering algorithm, we identified a cluster of patients characterized by higher leptin values and lower pro-inflammatory cytokines (TNF-α, IFN-γ and IL-6) who experienced longer PFS (13.2 vs 8.05 months; HR: 0.42 [0.18-0.93] p = 0.02) and OS (18.04 vs 12.09 mo; HR: 0.53 [0.25-1.29] p = 0.07).
CONCLUSIONS
CONCLUSIONS
Adipokines can play a crucial role to determining effectiveness of anti-cancer immunotherapy. The role of metabolic immune dysfunctions needs further pre-clinical validation and is currently investigated in the larger prospective cohort.
Identifiants
pubmed: 37668709
doi: 10.1007/s00262-023-03533-0
pii: 10.1007/s00262-023-03533-0
pmc: PMC10576666
doi:
Substances chimiques
Adipokines
0
Insulins
0
Interleukin-6
0
Leptin
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3803-3812Informations de copyright
© 2023. The Author(s).
Références
Rudin CM, Brambilla E, Faivre-Finn C, Sage J (2021) Small-cell lung cancer. Nat Rev Dis Primers 7(1):3. https://doi.org/10.1038/s41572-020-00235-0 .
Micke P, Faldum A, Metz T et al (2002) Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer–what limits limited disease? Lung Cancer 37(3):271–276
doi: 10.1016/S0169-5002(02)00072-7
pubmed: 12234695
Farago, AF, Keane FK (2018) Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res 7:69–79.
Paz-Ares L, Dvorkin M, Chen Y et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394(10212):1929–1939. https://doi.org/10.1016/S0140-6736(19)32222-6
doi: 10.1016/S0140-6736(19)32222-6
pubmed: 31590988
Goldman JW, Dvorkin M, Chen Y et al (2021) Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 22(1):51–65. https://doi.org/10.1016/S1470-2045(20)30539-8
doi: 10.1016/S1470-2045(20)30539-8
pubmed: 33285097
Horn L, Mansfield AS, Szczęsna A et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. NEJM 379:2220–2229
doi: 10.1056/NEJMoa1809064
pubmed: 30280641
Liu SV, Reck M, Mansfield AS et al (2021) Updated overall survival and PDL1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol 39(6):619–630
doi: 10.1200/JCO.20.01055
pubmed: 33439693
pmcid: 8078320
Reck M, Mok TSK, Mansfield A et al (2022) Brief report: exploratory analysis of maintenance therapy in patients with extensive-stage SCLC treated first line with atezolizumab plus carboplatin and etoposide. J Thorac Oncol 17(9):1122–1129. https://doi.org/10.1016/j.jtho.2022.05.016
doi: 10.1016/j.jtho.2022.05.016
pubmed: 35764236
Bria E, Garassino MC, Del Signore E et al (2022) Atezolizumab (ATZ) plus carboplatin (Cb) and etoposide (eto) in patients with untreated extensive-stage small cell lung cancer (ES-SCLC): Results from the interim analysis of MAURIS trial. ESMO 2022 - Poster session no 1533. Ann Oncol 33(suppl_7):S701–S712. https://doi.org/10.1016/annonc/annonc1074
Garcia Campelo MR, Domine Gomez M, De Castro Carpeno J et al (2022) Primary results from IMfirst, a phase IIIb open label safety study of atezolizumab (ATZ) + carboplatin (CB)/cisplatin (CP) + etoposide (ET) in an interventional real-world (RW) clinical setting of extensive-stage small cell lung cancer (ES-SCLC) in Spain. ESMO 2022 – Poster session no. 1531P. Ann Oncol 33(suppl_7):S701–S712. https://doi.org/10.1016/annonc/annonc1074
Isla D, Arriola E, M.R. Garcia Campelo MR et al (2022) Phase IIIb study of durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Preliminary efficacy results. ESMO 2022—Poster session no 1532. Ann Oncol (2022) 33 (suppl_7):S701–S712. https://doi.org/10.1016/annonc/annonc1074
McQuade JL, Daniel CR, Hess KR et al (2018) Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol 19(3):310–322. https://doi.org/10.1016/S1470-2045(18)30078-0
doi: 10.1016/S1470-2045(18)30078-0
pubmed: 29449192
pmcid: 5840029
Cortellini A, Bersanelli M, Buti S et al (2019) A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer 7(1):57. https://doi.org/10.1186/s40425-019-0527-y
doi: 10.1186/s40425-019-0527-y
pubmed: 30813970
pmcid: 6391761
Wang Z, Aguilar EG, Luna JI et al (2019) Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med 25(1):141–151
doi: 10.1038/s41591-018-0221-5
pubmed: 30420753
Shirakawa K, Yan X, Shinmura K et al (2016) Obesity accelerates T cell senescence in murine visceral adipose tissue. J Clin Invest 126(12):4626–4639. https://doi.org/10.1172/JCI88606
doi: 10.1172/JCI88606
pubmed: 27820698
pmcid: 5127667
Dudzinski SO, Bader JE, Beckermann KE et al (2021) Leptin augments antitumor immunity in obesity by repolarizing tumor-associated macrophages. J Immunol 207(12):3122–3130. https://doi.org/10.4049/jimmunol.2001152
doi: 10.4049/jimmunol.2001152
pubmed: 34772698
Clements VK, Long T, Long R, Figley C, Smith DMC, Ostrand-Rosenberg S (2018) Frontline science: High fat diet and leptin promote tumor progression by inducing myeloid-derived suppressor cells. J Leukoc Biol 103(3):395–407. https://doi.org/10.1002/JLB.4HI0517-210R
doi: 10.1002/JLB.4HI0517-210R
pubmed: 29345342
Pingili AK, Chaib M, Sipe LM et al (2021) Immune checkpoint blockade reprograms systemic immune landscape and tumor microenvironment in obesity-associated breast cancer. Cell Rep 35(12):109285. https://doi.org/10.1016/j.celrep.2021.109285 .
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419. https://doi.org/10.1007/BF00280883
doi: 10.1007/BF00280883
pubmed: 3899825
Wallace TM, Levy JC, Matthews DR (2004) An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med 21(6):568–576. https://doi.org/10.1111/j.1464-5491.2004.01218.x
doi: 10.1111/j.1464-5491.2004.01218.x
pubmed: 15154941
Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27(6):1487–1495. https://doi.org/10.2337/diacare.27.6.1487
doi: 10.2337/diacare.27.6.1487
pubmed: 15161807
Seymour L, Bogaerts J, Perrone A et al (2017) RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18(3):e143–e152. https://doi.org/10.1016/S1470-2045(17)30074-8 . Epub 2017 Mar 2.
Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i-xii, 1–253.
Irving BA, Weltman JY, Brock DW, Davis CK, Gaesser GA, Weltman A (2007) NIH ImageJ and Slice-O-Matic computed tomography imaging software to quantify soft tissue. Obesity (Silver Spring) 15(2):370–376. https://doi.org/10.1038/oby.2007.573
doi: 10.1038/oby.2007.573
pubmed: 17299110
Russo S, Kwiatkowski M, Govorukhina N, Bischoff R, Melgert BN (2021) meta-inflammation and metabolic reprogramming of macrophages in diabetes and obesity: the importance of metabolites. Front Immunol 12:746151. https://doi.org/10.3389/fimmu.2021.746151 .
Boutens L, Hooiveld GJ, Dhingra S, Cramer RA, Netea MG, Stienstra R (2018) Unique metabolic activation of adipose tissue macrophages in obesity promotes inflammatory responses. Diabetologia 61(4):942–953. https://doi.org/10.1007/s00125-017-4526-6
doi: 10.1007/s00125-017-4526-6
pubmed: 29333574
pmcid: 6448980
Barchetta I, Cimini FA, Ciccarelli G, Baroni MG, Cavallo MG (2019) Sick fat: the good and the bad of old and new circulating markers of adipose tissue inflammation. J Endocrinol Investig 42:1257–1272
doi: 10.1007/s40618-019-01052-3
Stienstra R, Stefan N (2013) Tipping the inflammatory balance: inflammasome activation distinguishes metabolically unhealthy from healthy obesity. Diabetologia. 2013;56:2343–2346.
Keegan A, Ricciuti B, Garden P et al (2020) Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. J Immunother Cancer 8(2):e000678. https://doi.org/10.1136/jitc-2020-000678 .
Shi Y, Liu X, Du J et al (2022) Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy. Thorac Cancer 13(2):219–227. https://doi.org/10.1111/1759-7714.14248
doi: 10.1111/1759-7714.14248
pubmed: 34825500
Schalper KA, Carleton M, Zhou M et al (2020) Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat Med 26(5):688–692. https://doi.org/10.1038/s41591-020-0856-x
doi: 10.1038/s41591-020-0856-x
pubmed: 32405062
pmcid: 8127102